Antitumor activity of cytotropic heterogeneous molecular lipids (CHML) on human breast cancer xenograft in nude mice

Anticancer Research

Volumn 21, Issue 4 A, 2001, Pages 2477-2482

  Zhan, Q ^a   Zhao, S C ^a   Xu, Z ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; CHML; Tumor suppression

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CYTOTROPIC HETEROGENEOUS MOLECULAR LIPID; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ALANINE TRANSAMINASE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; FATTY ACIDS, UNSATURATED; FEMALE; GROWTH INHIBITORS; HUMANS; LEUKOCYTE COUNT; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; VITAMINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035153351     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. CHML suppresses cell growth and induces apoptosis in multiple human tumor lines
2. Rosenberg
3. Management of locally advanced carcinoma of the breast by primary radiation therapy
4. Results of treating stage III carcinoma of the breast by primary radiation therapy
5. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: An active new regimen
6. Six-year results of a multimodality treatment strategy for locally advanced breast cancer
7. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumor considered too large for breast conserving surgery: Preliminary results of a randomized trial
8. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer
9. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: Comparison of quantitative polymerase chain reaction and immunocytochemical techniques
10. The hidden treasures of the primary tumor: Extended neoadjuvant chemotherapy plus GM-CSF in locally advanced cancer
11. Doxorubicicin gradients in human breast cancer
12. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin
13. Prognostic factors in locally advanced non-inflammatory breast cancer, long-term results following primary chemotherapy
14. Treatment of locally advanced breast cancer
15. Importance of nausea
16. Diagnosis and management of acute and chronic oral complication of nonsurgical cancer therapies
17. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis
18. Kinetics of macrophage subpopulations and expression of monocyte chemo-attractant protein-1 (MCP-1) in bleomycin-induced lung injury of rats studied by a novel monoclonal antibody against rat MCP-1
19. Long-term cardiac follows up 4-13 years post anthracycline therapy
20. Cardiotoxicity 4-20 years after completing anthracycline therapy
21. Mitoxantrone: An active, new antitumor agent with an improved therapeutic index